Filing excerpt
In October 2026, the Company announced an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to provide additional supply of Inmazeb® for U.S. preparedness against Ebola disease. Under the terms of the agreement, the Company expects to deliver a pre-specified number of treatment doses of Inmazeb each year to the U.S. government beginning in 2027 through 2031.